RxDoctor Payments Data

John Robinette, DPM

Podiatrist · Pine Bluff, ARNPI 1649254228

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Osiris Therapeutics Inc. at 43.1% of the total. Reporting peaked in 2019 at $171 and has fallen 92.0% since, to $14 in 2025. That places this record below the midpoint for podiatrist clinicians in AR, where the typical reported total is $1,089.

$287in general payments, 2019–2025

Across 10 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osiris Therapeutics Inc.$124
  • Integra Lifesciences Corporation$64
  • Paratek Pharmaceuticals, Inc.$31
  • Smith+Nephew$27
  • Nabriva Therapeutics, PLC$18
  • Organogenesis Inc.$11
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287 in reported general payments places this provider in the 20th percentile of 35 podiatrist providers in Arkansas.

See all podiatrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$147,977
Medicare patients
714
Services billed
1,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl85$1,124
Linezolid11$1,061
Gabapentin70$501
Clindamycin Hcl70$364
Methylprednisolone38$326
Doxycycline Hyclate29$322
Allopurinol52$280
Naproxen12$248
Prednisone23$247
Cephalexin20$179
Meloxicam65$149
Levofloxacin31$137
Clobetasol Propionate11$116
Hydrocortisone12$101
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$63

Paid to pharmacies, not to this prescriber.

Other podiatrist in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →